# Nuformix proposes Biovara acquisition to create respiratory drug development group

- Link: https://www.directorstalkinterviews.com/nuformix-proposes-biovara-acquisition-to-create-respiratory-drug-development-group/4121270037
- Published: 2026-11-19T10:58:00+00:00
- Author: Amilia Stone

Nuformix has proposed an all-share acquisition of UK pharmaceutical developer Biovara,
bringing together two respiratory drug programmes targeting lung fibrosis and lung
cancer-related cough.

The proposed transaction is structured as a merger of equals and would create a 
larger respiratory-focused drug development business with two complementary assets,
Nuformix’s NXP002 and Biovara’s LipAprep.

The proposed merger would bring together two programmes using established pharmaceutical
compounds in new formulations, with the aim of improving their potential for treating
respiratory conditions.

Nuformix’s NXP002 is an inhaled formulation of tranilast being developed for idiopathic
pulmonary fibrosis (IPF), progressive pulmonary fibrosis and other fibrotic interstitial
lung diseases. The programme has received Orphan Drug Designation from both the 
US Food and Drug Administration and the European Medicines Agency.

The treatment is designed to deliver tranilast directly to the lungs, potentially
achieving relevant local concentrations while limiting exposure elsewhere in the
body. Preclinical studies have reported anti-fibrotic and anti-inflammatory activity
in human IPF lung tissue, alongside evidence of activity in fibrosis-related pathways.

Biovara’s LipAprep is a proprietary lipid-based formulation of aprepitant, an established
medicine used to prevent chemotherapy-related nausea and vomiting. It is being developed
to treat persistent cough associated with lung cancer, where treatment options remain
limited.

Aprepitant has previously been assessed in clinical studies for lung cancer-related
cough. One controlled study reported a mean reduction of 30.3% in 24-hour cough 
frequency compared with placebo. LipAprep is intended to address limitations of 
the existing formulation and support more predictable drug exposure for longer-term
treatment.

LipAprep has completed a single-ascending-dose Phase 1 study, including evaluation
at doses of up to 750mg. Biovara is preparing for further clinical development, 
including multiple-dose assessment and a Phase 2 proof-of-concept study. Its formulation
has patent protection extending to at least 2045.

The companies believe the combination could provide a broader development pipeline
and opportunities to work with pharmaceutical companies interested in respiratory
treatments. Nuformix’s existing discussions with potential licensing and development
partners for NXP002 are continuing and are not expected to be delayed by the proposed
transaction.

Under the heads of terms, Nuformix would acquire the entire issued and to be issued
share capital of Biovara in exchange for new Nuformix shares. The transaction is
envisaged as a merger of equals, although the combined group’s valuation and final
terms have yet to be agreed.

_**Nuformix plc** ([LON:NFX](https://www.directorstalkinterviews.com/company/nuformix-plc/nfx.l))
is a pharmaceutical development company targeting unmet medical needs in fibrosis
and oncology using drug repurposing._

Share on:
